Addition of BTK inhibitor orelabrutinib to rituximab improved anti ...
However, the off-target inhibition of ibrutinib on interleukin-2 (IL-2)-inducible T cell kinase (ITK) may reduce rituximab’s antibody-dependent cellular cytotoxicity (ADCC) efficacy. Orelabrutinib …
Multifaceted Immunomodulatory Effects of the BTK Inhibitors …
2021年8月13日 · ITK overexpression in NK cells results in enhanced FcR-initiated killing but reduced NKG2D-initiated cytotoxicity ( Khurana et al., 2007 ). Overall, these studies reveal …
Bruton tyrosine kinase inhibitors in B-cell lymphoma: beyond the ...
2022年9月22日 · Ibrutinib inhibits rituximab-dependent NK cell-mediated cytotoxicity, while acalabrutinib, orelabrutinib, and fenebrutinib have no effect on ITK- and NK cell-mediated …
Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC …
Inhibition of ITK by ibrutinib modulates T-cell populations 28 and has been shown to suppress antibody-dependent cell-mediated cytotoxicity (ADCC) by natural killer (NK) cells in response …
Discovery of a highly potent and selective Bruton’s tyrosine kinase ...
2020年9月14日 · Given the fact that Ibrutinib could impair anti-CD20 antibodies exerted antibody drug-dependent NK-cell-mediated cytotoxicity (ADCC) due to the selectivity problem, we then …
Ibrutinib antagonizes rituximab-dependent NK cell–mediated …
We demonstrate that the abrogation of both rituximab’s and trastuzumab’s antitumor efficacy is a result of ibrutinib’s inhibition of FcR-stimulated NK cell function, specifically ADCC. Selective …
However, inhibition of interleukin-2 (IL-2)-inducible T cell kinase (ITK) by ibrutinib regulates T cell pop-ulations and suppresses NK-cell-mediated antibody-dependent cellular cytotoxicity …
Three BTK-Specific Inhibitors, in Contrast to Ibrutinib, Do
2014年12月6日 · As rituximab-combination chemotherapy is today’s standard of care in CD20 + B-cell malignancies, we previously investigated and determined ibrutinib antagonizes …
In short, we have discovered a novel highly selective covalent BTK kinase inhibitor CHMFL-BTK-85, which did not affect the NK-cell-mediated ADCC effects and showed good in vitro and in …
新淋视角丨宋玉琴教授：双剑合璧！利妥昔单抗基础上联合奥布替 …
1、奥布替尼具有最佳激酶选择性，对NK细胞上的ITK靶点的抑制作用很弱，不影响抗CD20单抗的ADCC效应. Hui Yu等在Molecular Therapy Oncolytics期刊上发表的一项研究【4】中，将奥布 …